The Therapeutic Goods Administration (TGA) delayed an announcement on the down-scheduling of CBD until late-December to consider further advice from a joint meeting of the Advisory Committees on Medicines and Chemicals Scheduling, Cannabiz has been told.

The TGA said public consultation on the interim decision to down-schedule low-dose CBD was open from September 9 to October 13 and no further consultation will take place.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

However, it told Cannabiz in a statement: “Following the consultation, the Delegate decided to seek further advice at the joint meeting of the Advisory Committees on Medicines Scheduling and Chemicals Scheduling held on November 5, 2020.

“Consequently, the final decision has been delayed to allow sufficient time for the Delegate to consider the advice of the Advisory Committees and the public submissions.”  

When the TGA announced its interim decision on down-scheduling CBD in September, it said a final decision would be published in November following the public consultation.

Medicinal Cannabis Industry Association (MCIA) chair Peter Crock said the body is meeting with stakeholders in Canberra on December 4 to continue dialogue across a number of areas and is “actively engaging with the TGA on down-scheduling and other matters”.

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...